Aktienanalyse zu Passage Bio Inc (PASG)PASGPassage Bio Inc

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Passage Bio Inc is a good buy right now due to its recent price increase of 15.94% over the last 5 days, which indicates positive momentum. Additionally, the stock is currently trading at $4, significantly below its 52-week high of $20, suggesting potential for upside. However, it is important to note that the company has reported negative earnings per share (EPS) of -2.44 in the last quarter, which highlights ongoing financial challenges. The RSI is at 75.774, indicating the stock is nearing overbought territory, which could present a risk if the momentum reverses.